New Insider Wei Ren Joins Ascentage Pharma, Files Initial Ownership
| Field | Detail |
|---|---|
| Company | Wei Ren |
| Form Type | 3 |
| Filed Date | Mar 23, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-ownership, form-3, new-insider, initial-statement
TL;DR
**New insider Wei Ren just filed their initial ownership with Ascentage Pharma, expect future trading disclosures.**
AI Summary
Wei Ren, a new insider at Ascentage Pharma Group International (CIK: 0002023311), filed a Form 3 on March 23, 2026, indicating their initial beneficial ownership of securities as of March 18, 2026. This filing is a standard requirement for new officers, directors, or significant shareholders, signaling their official connection to the company and the start of their reporting obligations. For investors, this matters because it introduces a new key individual whose future trading activity (buys or sells) will be publicly disclosed, offering insights into their confidence in the company's prospects.
Why It Matters
This filing introduces a new insider, Wei Ren, to Ascentage Pharma Group International, meaning their future stock transactions will be public, providing transparency for investors.
Risk Assessment
Risk Level: low — A Form 3 filing is a routine disclosure for new insiders and does not inherently indicate a positive or negative event for the company.
Analyst Insight
Investors should note Wei Ren's name and CIK (0002123015) to track any future Form 4 filings, which will disclose their buying or selling of Ascentage Pharma Group International stock, potentially signaling insider sentiment.
Key Players & Entities
- Wei Ren (person) — Reporting Person, new insider at Ascentage Pharma Group International
- Ascentage Pharma Group International (company) — Issuer of the securities
- 0002123015 (person) — CIK for Wei Ren
- 0002023311 (company) — CIK for Ascentage Pharma Group International
FAQ
What is the purpose of a Form 3 filing?
A Form 3, as filed by Wei Ren, is an 'Initial statement of beneficial ownership of securities.' It is required when a person becomes an officer, director, or beneficial owner of more than 10% of a class of a company's equity securities, disclosing their initial holdings.
When was this Form 3 filed and what is the period of report?
This Form 3 was filed on March 23, 2026, and accepted on the same day. The 'Period of Report' for the beneficial ownership is March 18, 2026.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 8.3 · Accepted 2026-03-23 19:24:04
Filing Documents
- marketforms-72699.html (3)
- marketforms-72699.xml (3) — 5KB
- poa.htm (EX-24) — 6KB
- 0001213900-26-033135.txt ( ) — 12KB
From the Filing
SEC FORM 3 SEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5 1. Name and Address of Reporting Person * Wei Ren (Last) (First) (Middle) 700 KING FARM BLVD, STE 510 (Street) ROCKVILLE MARYLAND 20850 (City) (State) (Zip) UNITED STATES (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares 8,964 D Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Options (1) 11/26/2035 Ordinary Shares 18,850 $ 8.14 (2) D Restricted share units (3) (3) Ordinary Shares 28,850 $ 0 D Explanation of Responses: 1. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025. 2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. 3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. Remarks: This form is filed using a special power of attorney. Thomas J. Knapp 03/23/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)